179 related articles for article (PubMed ID: 37369391)
1. Tobacco exposure primes the secretion of CCL21 positively associated with tertiary lymphoid structure and response to immunotherapy.
Yin X; Wang H; Li R; Song X; Zhang T; Liang Y; Chen YZ; Yu X; Mao Q; Xia W; Chen B; Xu L; Dong G; Jiang F
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37369391
[TBL] [Abstract][Full Text] [Related]
2. Lymphatic Metastasis of NSCLC Involves Chemotaxis Effects of Lymphatic Endothelial Cells through the CCR7-CCL21 Axis Modulated by TNF-α.
Zhang S; Wang H; Xu Z; Bai Y; Xu L
Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33158173
[TBL] [Abstract][Full Text] [Related]
3. Chemokine (C‑C motif) ligand 21/C‑C chemokine receptor type 7 triggers migration and invasion of human lung cancer cells by epithelial‑mesenchymal transition via the extracellular signal‑regulated kinase signaling pathway.
Zhong G; Chen L; Yin R; Qu Y; Bao Y; Xiao Q; Zhang Z; Shen Y; Li C; Xu Y; Zou Z; Tian H
Mol Med Rep; 2017 Jun; 15(6):4100-4108. PubMed ID: 28487957
[TBL] [Abstract][Full Text] [Related]
4. The role of CCL21/CCR7 chemokine axis in breast cancer-induced lymphangiogenesis.
Tutunea-Fatan E; Majumder M; Xin X; Lala PK
Mol Cancer; 2015 Feb; 14():35. PubMed ID: 25744065
[TBL] [Abstract][Full Text] [Related]
5. The C-terminal peptide of CCL21 drastically augments CCL21 activity through the dendritic cell lymph node homing receptor CCR7 by interaction with the receptor N-terminus.
Jørgensen AS; Brandum EP; Mikkelsen JM; Orfin KA; Boilesen DR; Egerod KL; Moussouras NA; Vilhardt F; Kalinski P; Basse P; Chen YH; Yang Z; Dwinell MB; Volkman BF; Veldkamp CT; Holst PJ; Lahl K; Goth CK; Rosenkilde MM; Hjortø GM
Cell Mol Life Sci; 2021 Nov; 78(21-22):6963-6978. PubMed ID: 34586443
[TBL] [Abstract][Full Text] [Related]
6. CCL21/CCR7 promotes G2/M phase progression via the ERK pathway in human non-small cell lung cancer cells.
Xu Y; Liu L; Qiu X; Jiang L; Huang B; Li H; Li Z; Luo W; Wang E
PLoS One; 2011; 6(6):e21119. PubMed ID: 21698152
[TBL] [Abstract][Full Text] [Related]
7. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
[TBL] [Abstract][Full Text] [Related]
8. CCL21/CCR7 axis activating chemotaxis accompanied with epithelial-mesenchymal transition in human breast carcinoma.
Li F; Zou Z; Suo N; Zhang Z; Wan F; Zhong G; Qu Y; Ntaka KS; Tian H
Med Oncol; 2014 Sep; 31(9):180. PubMed ID: 25142946
[TBL] [Abstract][Full Text] [Related]
9. Tumor hypoxia modulates podoplanin/CCL21 interactions in CCR7+ NK cell recruitment and CCR7+ tumor cell mobilization.
Tejchman A; Lamerant-Fayel N; Jacquinet JC; Bielawska-Pohl A; Mleczko-Sanecka K; Grillon C; Chouaib S; Ugorski M; Kieda C
Oncotarget; 2017 May; 8(19):31876-31887. PubMed ID: 28416768
[TBL] [Abstract][Full Text] [Related]
10. Iodine regulates G2/M progression induced by CCL21/CCR7 interaction in primary cultures of papillary thyroid cancer cells with RET/PTC expression.
Zhang YY; Liu ZB; Ye XG; Ren WM
Mol Med Rep; 2016 Oct; 14(4):3941-6. PubMed ID: 27574129
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of tertiary lymphoid structures in esophageal squamous cell carcinoma.
Deguchi S; Tanaka H; Suzuki S; Natsuki S; Mori T; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
BMC Cancer; 2022 Jun; 22(1):699. PubMed ID: 35751038
[TBL] [Abstract][Full Text] [Related]
12. CCL21/CCR7 prevents apoptosis via the ERK pathway in human non-small cell lung cancer cells.
Xu Y; Liu L; Qiu X; Liu Z; Li H; Li Z; Luo W; Wang E
PLoS One; 2012; 7(3):e33262. PubMed ID: 22438908
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma.
Liu Z; Meng X; Tang X; Zou W; He Y
Cancer Immunol Immunother; 2023 Jun; 72(6):1505-1521. PubMed ID: 36481914
[TBL] [Abstract][Full Text] [Related]
14. Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy.
Sand LG; Berghuis D; Szuhai K; Hogendoorn PC
Cancer Immunol Immunother; 2016 Aug; 65(8):995-1002. PubMed ID: 27369431
[TBL] [Abstract][Full Text] [Related]
15. Follicle-like tertiary lymphoid structures: A potential biomarker for prognosis and immunotherapy response in patients with laryngeal squamous cell carcinoma.
Liang H; Zhang Z; Guan Z; Zheng S; Lou J; Liu W; Cai Q; Si Y
Front Immunol; 2023; 14():1096220. PubMed ID: 36776859
[TBL] [Abstract][Full Text] [Related]
16. Ectopic lymphoid tissue alters the chemokine gradient, increases lymphocyte retention and exacerbates murine ileitis.
McNamee EN; Masterson JC; Jedlicka P; Collins CB; Williams IR; Rivera-Nieves J
Gut; 2013 Jan; 62(1):53-62. PubMed ID: 22267601
[TBL] [Abstract][Full Text] [Related]
17. Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy.
Sah VR; Jespersen H; Karlsson J; Nilsson LM; Bergqvist M; Johansson I; Carneiro A; Helgadottir H; Levin M; Ullenhag G; Ståhlberg A; Olofsson Bagge R; Nilsson JA; Ny L
Cancer Res Commun; 2023 May; 3(5):884-895. PubMed ID: 37377898
[TBL] [Abstract][Full Text] [Related]
18. CCL21 and IFNγ recruit and activate tumor specific T cells in 3D scaffold model of breast cancer.
Phan-Lai V; Kievit FM; Florczyk SJ; Wang K; Disis ML; Zhang M
Anticancer Agents Med Chem; 2014 Feb; 14(2):204-10. PubMed ID: 24237220
[TBL] [Abstract][Full Text] [Related]
19. Chemokine axes in breast cancer: factors of the tumor microenvironment reshape the CCR7-driven metastatic spread of luminal-A breast tumors.
Weitzenfeld P; Kossover O; Körner C; Meshel T; Wiemann S; Seliktar D; Legler DF; Ben-Baruch A
J Leukoc Biol; 2016 Jun; 99(6):1009-25. PubMed ID: 26936935
[TBL] [Abstract][Full Text] [Related]
20. Tertiary lymphoid structure and B-cell-related pathways: A potential target in tumor immunotherapy.
Qin M; Jin Y; Pan LY
Oncol Lett; 2021 Dec; 22(6):836. PubMed ID: 34712360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
